Lantheus Holdings, Inc. (NasdaqGM:LNTH) will look for acquisitions. Mary Anne Heino, President and Chief Executive officer said, "We continue to seek ways to further expand our portfolio, evaluating several opportunities to collaborate, in-license or acquire additional assets which match our strategic priorities. We are particularly pleased and focused on late-stage diagnostic and therapeutic product opportunities in oncology that complement our existing portfolio.

In addition, certain early-stage opportunities also align with the strategy that drives our pharma services business. For example, we recently entered into a collaboration agreement with Radiopharm Theranostics. Radiopharm is an Australian-based developer of platforms of radiopharmaceutical products for both diagnostic and therapeutic uses.

Radiopharm plans to initiate a Phase I therapeutic trial for patients with PD-L1 positive non-small cell lung cancer in Australia. Lantheus will supply our diagnostic product candidate, NM-01, to Radiopharm for their clinical trials, to be used as a clinical research tool to assess PD-L1 expression in patient selection. We have also retained the option to expand our partnership to additional assets in Radiopharm's pipeline".